
Personalised Medicine
Pharmacogenomics in the pocket of every patient? A prototype based on quick response codes -- Samwald and Adlassnig
Journal of the American Medical Informatics Association jamia.bmj.com doi:10.1136/amiajnl-2012-001275Public release date: 16-Aug-2012 [ Print | E-mail |
Creating a future of personalized medicine: U-M forms joint venture for DNA diagnostics
Nvidia Tesla GPUs to power EasyGenomics service for affordable DNA sequencing
Led by tissue tests to aid drug therapy decisions, the personalized medicine testing market exceeded $28 billion in 2011, according to Kalorama Information. The healthcare market research publisher includes in its analysis all tests that are used to determine the appropriate therapeutic on an individual patient. [See also: GE makes investment in NanoString Technologies ] This broad scope includes new molecular tests based on proven biomarkers, as well as routine glucose and microbial identification tests. The dynamic part of the market is the new tests, and according to Kalorama's report, "World Market for Personalized Medicine Diagnostics," the tests that have turned personalized medicine from concept to reality are tissue tests that determine therapy for cancer. These will experience better than average IVD industry revenue growth rates in the next five years.
Personalized medicine market in growth mode
Begun in 2008, the "1000 Genomes Project" aims to sequence 1000 genomes and gain a deeper understanding of what genetic variations may put people at risk for disease. When the Human Genome Project got underway in 1990 it was expected to take 15 years to sequence the over 3 billion chemical base pairs that spell out our genetic code. In true Moore’s Law tradition the emergence of faster and more efficient sequencing technologies along the way led to the Project’s early completion in 2003. Today, 22 years after scientists first committed to the audacious goal of sequencing the genome, the next generation of sequencers are setting their sites much higher. About a thousand times higher.

